FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173706377> ?p ?o ?g. }

• W3173706377 endingPage "17" @default.
• W3173706377 startingPage "5" @default.
• W3173706377 abstract "Background . Over the past 10–15 years, there has been a clearer understanding of the processes occurring in cells of the primary glioblastoma. However, the change in MGMT gene expression and its role after disease relapse remain understudied. Purpose : to study changes in MGMT gene expression in case of recurrent primary glioblastoma after the standard therapy; to determine influence of clinical factors and MGMt gene expression on relapse-free survival of patients. Materials and Methods . We carried out a prospective analysis of clinical and molecular genetic characteristics of 21 patients aged from 28 to 63 with primary glioblastoma before and after recurrence. Relative mRna expression of MGMT gene and mutations in IDH1/IDH2 genes were determined in surgical biopsies using PCR techniques. after the first surgery, all patients received radiation therapy (60 Gy) and chemotherapy with adjuvant temozolomide (2–18 cycles). the second-line chemotherapy was performed in 17 (80.9 %) patients, and 8 patients received (47 %, 8/17) temozolomide. Results. the relationship between the progression-free survival (PFs) and mRna expression of MGMT gene (73.5 vs 33 weeks, p=0.013) and objective response to therapy (88 vs 36 weeks, p=0.046) was found. The number of cycles of first-line chemotherapy with temozolomide influenced the duration of the first PFs (65 weeks vs 21.5 weeks, p=0,07). the first PFs was not affected by patients’ age (p=0.64), sex (p=0.17), Karnofsky performance scale index (p=0.43), extent of brain damage (p=0.41) and extent of the resection (p=0.27). after onset of relapse, mRna expression of MGMT gene remained the same, being 66.7 % (14/21). The increased expression was observed in 23.8 % (5/21) of cases, and decreased gene expression was observed in 9.5 % (2/21) of cases. the second PFs was affected by the extent of tumor resection, although there were no statistically significant differences (p=0.52). the effect of mRna expression of MGMT gene on the median second PFs was not revealed (p=0.39). no objective response to therapy was found in patients with a low mRna expression of MGMT gene. Conclusion . Recurrent glioblastoma becomes more resistant to further therapy. With the development of tumor recurrence, the predictive value of MGMT gene is lost and the role of the extent of cytoreductive surgery increases." @default.
• W3173706377 created "2021-07-05" @default.
• W3173706377 creator A5004557757 @default.
• W3173706377 creator A5010719185 @default.
• W3173706377 creator A5016288921 @default.
• W3173706377 creator A5036437921 @default.
• W3173706377 creator A5036477674 @default.
• W3173706377 creator A5038749769 @default.
• W3173706377 creator A5041485936 @default.
• W3173706377 creator A5042383135 @default.
• W3173706377 creator A5053860932 @default.
• W3173706377 creator A5084612652 @default.
• W3173706377 creator A5085241792 @default.
• W3173706377 date "2021-06-29" @default.
• W3173706377 modified "2023-10-18" @default.
• W3173706377 title "CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS" @default.
• W3173706377 cites W1482210527 @default.
• W3173706377 cites W1537699783 @default.
• W3173706377 cites W1607524397 @default.
• W3173706377 cites W1959444207 @default.
• W3173706377 cites W1972827668 @default.
• W3173706377 cites W1975104842 @default.
• W3173706377 cites W1978853965 @default.
• W3173706377 cites W1988011020 @default.
• W3173706377 cites W2007425554 @default.
• W3173706377 cites W2012946111 @default.
• W3173706377 cites W2021210732 @default.
• W3173706377 cites W2044792043 @default.
• W3173706377 cites W2052491055 @default.
• W3173706377 cites W2065845336 @default.
• W3173706377 cites W2076491810 @default.
• W3173706377 cites W2079232919 @default.
• W3173706377 cites W2099603826 @default.
• W3173706377 cites W2105100844 @default.
• W3173706377 cites W2119996840 @default.
• W3173706377 cites W2124736921 @default.
• W3173706377 cites W2129418270 @default.
• W3173706377 cites W2146904439 @default.
• W3173706377 cites W2151032990 @default.
• W3173706377 cites W2158681922 @default.
• W3173706377 cites W2162643152 @default.
• W3173706377 cites W2336951703 @default.
• W3173706377 cites W2366536035 @default.
• W3173706377 cites W2589333368 @default.
• W3173706377 cites W2594077503 @default.
• W3173706377 cites W2599750069 @default.
• W3173706377 cites W2776406960 @default.
• W3173706377 cites W2886317495 @default.
• W3173706377 cites W2953775936 @default.
• W3173706377 cites W3001610059 @default.
• W3173706377 cites W407665433 @default.
• W3173706377 cites W4234865248 @default.
• W3173706377 doi "https://doi.org/10.21294/1814-4861-2021-20-3-5-17" @default.
• W3173706377 hasPublicationYear "2021" @default.
• W3173706377 type Work @default.
• W3173706377 sameAs 3173706377 @default.
• W3173706377 citedByCount "0" @default.
• W3173706377 crossrefType "journal-article" @default.
• W3173706377 hasAuthorship W3173706377A5004557757 @default.
• W3173706377 hasAuthorship W3173706377A5010719185 @default.
• W3173706377 hasAuthorship W3173706377A5016288921 @default.
• W3173706377 hasAuthorship W3173706377A5036437921 @default.
• W3173706377 hasAuthorship W3173706377A5036477674 @default.
• W3173706377 hasAuthorship W3173706377A5038749769 @default.
• W3173706377 hasAuthorship W3173706377A5041485936 @default.
• W3173706377 hasAuthorship W3173706377A5042383135 @default.
• W3173706377 hasAuthorship W3173706377A5053860932 @default.
• W3173706377 hasAuthorship W3173706377A5084612652 @default.
• W3173706377 hasAuthorship W3173706377A5085241792 @default.
• W3173706377 hasBestOaLocation W31737063771 @default.
• W3173706377 hasConcept C126322002 @default.
• W3173706377 hasConcept C143998085 @default.
• W3173706377 hasConcept C2776194525 @default.
• W3173706377 hasConcept C2776694085 @default.
• W3173706377 hasConcept C2777389519 @default.
• W3173706377 hasConcept C2780739268 @default.
• W3173706377 hasConcept C2780964509 @default.
• W3173706377 hasConcept C502942594 @default.
• W3173706377 hasConcept C509974204 @default.
• W3173706377 hasConcept C71924100 @default.
• W3173706377 hasConceptScore W3173706377C126322002 @default.
• W3173706377 hasConceptScore W3173706377C143998085 @default.
• W3173706377 hasConceptScore W3173706377C2776194525 @default.
• W3173706377 hasConceptScore W3173706377C2776694085 @default.
• W3173706377 hasConceptScore W3173706377C2777389519 @default.
• W3173706377 hasConceptScore W3173706377C2780739268 @default.
• W3173706377 hasConceptScore W3173706377C2780964509 @default.
• W3173706377 hasConceptScore W3173706377C502942594 @default.
• W3173706377 hasConceptScore W3173706377C509974204 @default.
• W3173706377 hasConceptScore W3173706377C71924100 @default.
• W3173706377 hasIssue "3" @default.
• W3173706377 hasLocation W31737063771 @default.
• W3173706377 hasLocation W31737063772 @default.
• W3173706377 hasOpenAccess W3173706377 @default.
• W3173706377 hasPrimaryLocation W31737063771 @default.
• W3173706377 hasRelatedWork W1970674393 @default.
• W3173706377 hasRelatedWork W2036862336 @default.
• W3173706377 hasRelatedWork W2073885660 @default.

• next